Aptimmune

St Louis, United States

Aptimmune is a biotechnology company that specializes on developing mucosal vaccines for swine.

Jan 2022

Convertible Note

Top Investors

Arsenal Capital PartnersCultivation CapitalKemin IndustriesThe Yield LabIllinois Ventures

19,000+ verified contacts

Emails, phones & LinkedIn profiles

Who are Aptimmune's investors?

Aptimmune's investors include Arsenal Capital Partners, Cultivation Capital, Kemin Industries, The Yield Lab, Illinois Ventures.

Where is Aptimmune headquartered?

Aptimmune is headquartered in St Louis, United States.

What does Aptimmune do?

Aptimmune is a biotechnology company that specializes on developing mucosal vaccines for swine.

What stage is Aptimmune at?

Aptimmune is at the Convertible Note stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 10, 2022.

MLA

"Aptimmune — Funding & Investors." VCBacked, January 10, 2022, https://www.vcbacked.co/company/aptimmune. Accessed July 1, 2026.

APA

VCBacked. (2022). Aptimmune — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/aptimmune

Wikipedia (cite web)

{{cite web |title=Aptimmune — Funding & Investors |url=https://www.vcbacked.co/company/aptimmune |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 10, 2022.